The presence of dMMR has significant clinical implications. Tumors with dMMR often exhibit a high mutation burden, making them more likely to respond to immunotherapy, particularly checkpoint inhibitors like pembrolizumab and nivolumab. These therapies can unleash the body's immune system to target and destroy cancer cells more effectively.
